Neurocrine Biosciences Inc (NBIX) Stock Analysis and Metrics

Neurocrine Biosciences

NASDAQ: NBIX

$175.78 ▲ +1.63 (+0.94%)

At close: Jul 24, 2026 · 3:59 PM UTC

Financial Ratios

Market Cap17.66 Bn

P/E26.41

P/S5.69

Div. Yield0.00

Revenue Growth (1y) (Qtr)42.25

Add ratio to table…

About

Neurocrine Biosciences is a neuroscience focused biopharmaceutical company dedicated to discovering, developing, and commercializing treatments for neurological, psychiatric, endocrine, and immunological disorders. The company’s portfolio includes FDA approved products such as INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease, CRENESSITY for classic congenital adrenal hyperplasia, and collaborative therapies for endometriosis and uterine fibroids with AbbVie. Neurocrine also maintains a deep pipeline of small molecules, peptides, proteins, antibodies, conjugates, and gene therapies targeting major depressive disorder, schizophrenia, epilepsy, obesity, and other conditions. The company’s simple purpose is to relieve suffering for people with great needs.

Revenue is generated primarily from net product sales of INGREZZA and CRENESSITY. INGREZZA net product sales were $2.51 billion in 2025, $2.31 billion in 2024, and $1.84 billion in 2023. CRENESSITY generated $301.2 million in net product sales during its first full year of launch in 2025. Additional revenue arises from collaboration and license agreements, including royalties and milestone payments related to elagolix. The company sells its products in the United States through specialty pharmacy providers, wholesale distributors, and specialty distributors, supported by a specialized sales force of approximately 600 professionals focused on neurology, psychiatry, long term care, and rare diseases. INGREZZA accounted for over 80% of total net product sales in each of the last three years.

Neurocrine Biosciences holds a strong position in the neuroscience and rare disease markets, competing principally with Teva Pharmaceuticals’ AUSTEDO for the treatment of tardive dyskinesia and Huntington’s disease chorea. The company’s competitive advantages stem from its proprietary VMAT2 biology expertise, a robust pipeline of late stage candidates such as osavampator for major depressive disorder and direclidine for schizophrenia, and first in class approvals for CRENESSITY in congenital adrenal hyperplasia. Intellectual property protection, including multiple patents expiring between 2027 and 2041 for INGREZZA and between 2035 and 2046 for CRENESSITY, further reinforces its market stance. The company invests heavily in research and development, allocating approximately 20% of revenue to fund its clinical and preclinical programs.

The customer base consists of specialty pharmacy providers, wholesale distributors, and specialty distributors that dispense INGREZZA to patients with tardive dyskinesia and Huntington’s disease chorea. CRENESSITY is distributed through a single specialty pharmacy provider owing to its rare disease focus. Physicians specializing in neurology, psychiatry, endocrinology, and long term care prescribe the therapies, while patients receiving treatment include those with tardive dyskinesia, chorea associated with Huntington’s disease, classic congenital adrenal hyperplasia, endometriosis, and uterine fibroids. Collaboration with AbbVie also provides access to its commercial networks for elagolix based products. In October 2025 the company announced plans to expand its sales force for INGREZZA and CRENESSITY to increase prescriber reach and support upcoming product launches.

Investment Thesis

▲ Bull case

The company has demonstrated robust top line momentum with net product sales exceeding eight hundred ten million in the first quarter driven by double digit growth in INGREZZA and accelerating adoption of Cranesity. The underlying demand for INGREZZA remains strong as approximately ninety% of the estimated eight hundred thousand tardive dyskinesia patients in the United States are not yet receiving standard of care VMAT2 inhibitor therapy leaving a sizable untapped market. Management reaffirmed full year INGREZZA guidance of two point seven to two point eight billion dollars indicating confidence in sustained volume growth and pricing stability. The recent acquisition of Soleno Therapeutics adds VYKAT XR which addresses hyperphagia in Prader Willi syndrome a rare disease with high unmet need and provides an immediate complementary revenue stream that can be cross sold to the existing endocrinology sales force.
The research and development pipeline is advancing with multiple phase one and phase two programs enrolling and several pivotal data readouts anticipated in twenty twenty seven including osavampitor for major depressive disorder dereclidine for schizophrenia and NBIP twenty eleven eighteen for obesity. These upcoming catalysts have the potential to diversify revenue beyond the current franchises and reduce reliance on any single product. Early clinical signals from the gene therapy program for Friedreichs ataxia and the CRF2 agonist for obesity suggest a differentiated mechanism that could capture premium pricing in underserved markets. The company's strong cash generation from commercial products supports continued investment in these high potential projects without jeopardizing financial flexibility.
The ongoing sales force expansion is designed to increase depth and breadth of prescriber engagement especially in under penetrated segments for both INGREZZA and Cranesity which should translate into higher new patient start rates and improved persistency over the next quarters. Real world evidence showing greater treatment persistence for INGREZZA compared to deuterated tetrabenazine supports a durable competitive advantage that can protect market share against emerging alternatives. Additionally the recent publication of expert recommendations for glucocorticoid dose reduction in patients treated with Cranesity reinforces its positioning as a standard of care therapy likely to drive further adoption among endocrinologists. Together these factors suggest that the company is well positioned to achieve record net product sales in twenty twenty six and sustain growth beyond.

The company has demonstrated robust top line momentum with net product sales exceeding eight hundred ten million in the first quarter driven by double digit growth in INGREZZA and accelerating adoption of Cranesity. The underlying demand for INGREZZA remains strong as approximately ninety% of the estimated eight hundred thousand tardive dyskinesia patients in the United States are not yet receiving standard of care VMAT2 inhibitor therapy leaving a sizable untapped market. Management reaffirmed full year INGREZZA guidance of two point seven to two point eight billion dollars indicating confidence in sustained volume growth and pricing stability. The recent acquisition of Soleno Therapeutics adds VYKAT XR which addresses hyperphagia in Prader Willi syndrome a rare disease with high unmet need and provides an immediate complementary revenue stream that can be cross sold to the existing endocrinology sales force.
The research and development pipeline is advancing with multiple phase one and phase two programs enrolling and several pivotal data readouts anticipated in twenty twenty seven including osavampitor for major depressive disorder dereclidine for schizophrenia and NBIP twenty eleven eighteen for obesity. These upcoming catalysts have the potential to diversify revenue beyond the current franchises and reduce reliance on any single product. Early clinical signals from the gene therapy program for Friedreichs ataxia and the CRF2 agonist for obesity suggest a differentiated mechanism that could capture premium pricing in underserved markets. The company's strong cash generation from commercial products supports continued investment in these high potential projects without jeopardizing financial flexibility.
The ongoing sales force expansion is designed to increase depth and breadth of prescriber engagement especially in under penetrated segments for both INGREZZA and Cranesity which should translate into higher new patient start rates and improved persistency over the next quarters. Real world evidence showing greater treatment persistence for INGREZZA compared to deuterated tetrabenazine supports a durable competitive advantage that can protect market share against emerging alternatives. Additionally the recent publication of expert recommendations for glucocorticoid dose reduction in patients treated with Cranesity reinforces its positioning as a standard of care therapy likely to drive further adoption among endocrinologists. Together these factors suggest that the company is well positioned to achieve record net product sales in twenty twenty six and sustain growth beyond.

▼ Bear case

Despite strong current performance the company remains heavily dependent on INGREZZA for the majority of its revenue and any slowdown in growth due to market saturation increased competition from generic or alternative VMAT2 inhibitors or changes in prescribing patterns could disproportionately affect overall financial results. The tardive dyskinesia market while still underpenetrated may experience slower than expected adoption as payers tighten formulary restrictions and rebate pressures intensify under the Inflation Reduction Act environment. Management noted gross to net pressure for Cranesity arising from commercial copay resets indicating that pricing concessions could erode margins as the product scales. These factors suggest that upside surprises may be limited if the core franchises encounter resistance.
The acquisition of Soleno Therapeutics while adding a new product VYKAT XR introduces integration risk including potential cultural clashes duplication of commercial functions and unexpected costs that could dilute the anticipated synergies. The purchase price represents a significant multiple of Soleno's current sales and any delay in achieving market uptake for hyperphagia therapy in Prader Willi syndrome would weigh on earnings and raise questions about capital allocation efficiency. Furthermore the company disclosed that financial guidance for the combined entity will be withheld until after the transaction closes creating uncertainty for investors regarding near term earnings prospects.
The pipeline while rich in early stage programs faces inherent execution risk with many phase one and phase two studies still years away from potential approval and no guarantee that positive data will translate into successful commercial products. The anticipated phase three readouts for osavampitor in major depressive disorder and dereclidine in schizophrenia are not expected until twenty twenty seven meaning that near term catalyst flow is limited and investors may have to rely on existing products for longer than hoped. Additionally the obesity program NBIP twenty eleven eighteen is still in phase one and any setback could delay diversification efforts beyond the core neurology and endocrinology franchises. This extended timeline increases the vulnerability of the company to shifts in payer policy or competitive entrants before new products reach market.

Despite strong current performance the company remains heavily dependent on INGREZZA for the majority of its revenue and any slowdown in growth due to market saturation increased competition from generic or alternative VMAT2 inhibitors or changes in prescribing patterns could disproportionately affect overall financial results. The tardive dyskinesia market while still underpenetrated may experience slower than expected adoption as payers tighten formulary restrictions and rebate pressures intensify under the Inflation Reduction Act environment. Management noted gross to net pressure for Cranesity arising from commercial copay resets indicating that pricing concessions could erode margins as the product scales. These factors suggest that upside surprises may be limited if the core franchises encounter resistance.
The acquisition of Soleno Therapeutics while adding a new product VYKAT XR introduces integration risk including potential cultural clashes duplication of commercial functions and unexpected costs that could dilute the anticipated synergies. The purchase price represents a significant multiple of Soleno's current sales and any delay in achieving market uptake for hyperphagia therapy in Prader Willi syndrome would weigh on earnings and raise questions about capital allocation efficiency. Furthermore the company disclosed that financial guidance for the combined entity will be withheld until after the transaction closes creating uncertainty for investors regarding near term earnings prospects.
The pipeline while rich in early stage programs faces inherent execution risk with many phase one and phase two studies still years away from potential approval and no guarantee that positive data will translate into successful commercial products. The anticipated phase three readouts for osavampitor in major depressive disorder and dereclidine in schizophrenia are not expected until twenty twenty seven meaning that near term catalyst flow is limited and investors may have to rely on existing products for longer than hoped. Additionally the obesity program NBIP twenty eleven eighteen is still in phase one and any setback could delay diversification efforts beyond the core neurology and endocrinology franchises. This extended timeline increases the vulnerability of the company to shifts in payer policy or competitive entrants before new products reach market.

Segments Breakdown of Revenue (2025)

Peer Comparison

Companies in the Drug Manufacturers - Specialty & Generic

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	HLN	Haleon plc	88.07 Bn	103.29	6.00	11.45 Bn
2	TEVA	Teva Pharmaceutical Industries Ltd	35.75 Bn	23.02	2.06	16.63 Bn
3	ZTS	Zoetis Inc.	31.84 Bn	12.05	3.35	9.05 Bn
4	TAK	Takeda Pharmaceutical Co Ltd	27.18 Bn	-10.29	0.59	28.76 Bn
5	UTHR	UNITED THERAPEUTICS Corp	23.09 Bn	17.93	7.28	-
6	RDHL	RedHill Biopharma Ltd.	21.32 Bn	2,931.66	2.24	-
7	VTRS	Viatris Inc	19.96 Bn	-67.32	1.37	14.34 Bn
8	NBIX	Neurocrine Biosciences Inc	17.66 Bn	26.41	5.69	-

Research Tools

Developers

About

Investment Thesis

Product and Service Breakdown of Revenue (2025)

Segments Breakdown of Revenue (2025)

Peer Comparison

Research Tools

Developers

About

Investment Thesis

Product and Service Breakdown of Revenue (2025)

Segments Breakdown of Revenue (2025)

Peer Comparison

Create an account

Sign In

Reset Password